Ratings by Truist Securities (Gregory Renza)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/9/2026 | Zymeworks | ZYME | New Coverage | Buy (N/A) |
23.93 (24.49) |
2.34% | Details | |
| 6/9/2026 | Jazz Pharmaceuticals | JAZZ | New Coverage | Buy (N/A) |
232.04 (231.14) |
-0.39% | Details | |
| 6/2/2026 | Fulcrum Therapeutics | FULC | Downgrade | Hold (Buy) |
6.92 (3.93) |
-43.21% | Details | |
| 5/27/2026 | Genmab A/S | GMAB | New Coverage | Buy (N/A) |
26.89 (25.93) |
-3.57% | Details | |
| 5/27/2026 | Viking Therapeutic | VKTX | New Coverage | Buy (N/A) |
30.80 (36.83) |
19.58% | Details | |
| 5/18/2026 | Revolution | RVMD | New Coverage | Buy (N/A) |
145.66 (166.96) |
14.62% | Details | |
| 2/4/2026 | Xencor, Inc. | XNCR | Maintain | Buy (N/A) |
|
Details |
